RxDoctor Payments Data

Anusha Veeravanallur Appuswamy, MD

Endocrinology, Diabetes & Metabolism · Barberton, OHNPI 1326490343

Payments from drug & device makers

$476in general payments, 2019–2025

Across 25 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$134
  • Lilly USA, LLC$99
  • Dexcom, Inc.$47
  • Tandem Diabetes Care, Inc.$34
  • Medtronic$31
  • GRT US Holding, Inc.$31
  • plus $100 from 5 others

What the payments were for

  • Food & beverage$476100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$476 in reported general payments places this provider in the 30th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$27,875
Medicare patients
166
Services billed
444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide113$120,000
OzempicSemaglutide63$73,286
JardianceEmpagliflozin51$57,454
Humulin R U-500 KwikpenInsulin Regular, Human19$41,996
MounjaroTirzepatide31$37,669
TymlosAbaloparatide13$32,773
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$20,693
RybelsusSemaglutide11$19,585
ProliaDenosumab11$17,533
FarxigaDapagliflozin Propanediol12$16,812
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/715$13,435
Lantus SolostarInsulin Glargine,hum.Rec.Anlog93$13,432
Humalog Kwikpen U-100Insulin Lispro26$10,067
Nano 2nd Gen Pen NeedlePen Needle, Diabetic65$9,458
Insulin Lispro Kwikpen U-100Insulin Lispro43$8,382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$99$167,681194 claims
Novo NordiskOzempic, Rybelsus$134$92,87174 claims
Radius Health, Inc.Tymlos$16$32,77313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Barberton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →